Rocket Pharma gets FDA review extension review of gene therapy

Rocket Pharmaceuticals, Inc. (NASDAQ: NASDAQ:RCKT) announced that the U.S. Food and Drug Administration (FDA) has extended the Priority Review period for its Biologics License Application (BLA) for KRESLADI™, a gene therapy for severe Leukocyte Adhesion Deficiency-I (LAD-I).